Updated:
Terra Magnum Capital Partners
Terra Magnum Capital Partners is a China-focused private equity firm with over $800 million in assets under management. The firm has made 12 investments,...
Terra Magnum Capital Partners
Terra Magnum Capital Partners is a China-focused private equity firm with over $800 million in assets under management. The firm has made 12 investments, including a Series C investment in Iambic Therapeutics on November 10, 2025. Terra Magnum Capital Partners has also achieved 8 portfolio exits, with Maze Therapeutics being its most recent exit on January 31, 2025.
General information
Firm type
Private Equity
Year founded
2016
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Frequently asked questions
What investment stages does Terra Magnum Capital Partners target?
The firm targets a broad range: seed, start-up, early-stage venture, growth, expansion, and PIPE transactions. This full-lifecycle approach allows Terra Magnum to deploy capital from initial formation rounds through to pre-IPO placements. The multi-stage mandate is structured to retain exposure to portfolio companies as they mature, rather than exiting at a single inflection point.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: